Cargando…
Peripheral absolute eosinophil count identifies the risk of serious immune-related adverse events in non-small cell lung cancer
BACKGROUND: Immune-related adverse events (irAEs) have drawn a lot of attention lately as a result of the predominance of immunotherapy in advanced non-small cell lung cancer (NSCLC). However, the clinical evidence for irAEs in real life is limited. In this paper, the occurrence of irAEs in Chinese...
Autores principales: | Wu, Yan, Li, Dapeng, Wu, Mengyao, Yang, Ying, Shen, Meng, Chen, Kai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608122/ https://www.ncbi.nlm.nih.gov/pubmed/36313675 http://dx.doi.org/10.3389/fonc.2022.1004663 |
Ejemplares similares
-
Absolute Lymphocyte Count Predicts Immune-Related Adverse Events in Patients With Non-Small-Cell Lung Cancer Treated With Nivolumab Monotherapy: A Multicenter Retrospective Study
por: Egami, Saeka, et al.
Publicado: (2021) -
Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysis
por: Ma, Yan, et al.
Publicado: (2022) -
Low Multiplication Value of Absolute Monocyte Count and Absolute Lymphocyte Count at Diagnosis May Predict Poor Prognosis in Neuroblastoma
por: Tamura, Akihiro, et al.
Publicado: (2020) -
Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer
por: Baroz, Angel R, et al.
Publicado: (2021) -
Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review
por: Ouyang, Tao, et al.
Publicado: (2021)